StockData
Opus Genetics, Inc. logo

Opus Genetics, Inc. (IRD) stock

IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$3.92−0.13 (-3.21%)

Close on Nov 18, 2026Market cap $326.13MP/E –Yield –

Opus Genetics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2020 it was -$6.80M.

Annual free cash flow

PeriodPeriod endValueChange
FY2020Dec 31, 2020-$6.80M–
FY2019Dec 31, 2019-$3.62M–

More Opus Genetics figures

See a number that looks wrong?